BTS
ADVM

BB&T Securities’s Adverum Biotechnologies ADVM Stock Holding History

BB&T Securities’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$85K Buy
+1,550
New +$175K ﹤0.01% 1581

Other funds holding ADVM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

BB&T Securities's ADVM Position: Q3 2019 in Review

BB&T Securities opened a new position in Adverum Biotechnologies (ADVM) in Q3 2019: 1,550 shares worth $85K. The stake represents ﹤0.01% of the portfolio and ranks #1581 among its holdings.

99 funds tracked by Wall St. Rank hold ADVM as of Q3 2019.

  • BB&T Securities held 1,550 shares of Adverum Biotechnologies worth $85K as of Q3 2019.
  • Adverum Biotechnologies was a new BB&T Securities position in Q3 2019.
  • Adverum Biotechnologies made up ﹤0.01% of BB&T Securities's portfolio in Q3 2019, its #1581 holding.
  • 99 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2019.

Based on BB&T Securities's 13F filing for Q3 2019, filed 30 Oct 2019.